泰恩康 (301263.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

161.5x

Market Cap

CNY 9.37B

MomentumView details →

1D Return

−3.57%

YTD Return

−32.39%

RSI (14)

49.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

161.5x

Market Cap

CNY 9.37B

RSI (14)

49.0

MomentumView details →

1D Return

−3.57%

YTD Return

−32.39%

ProfitabilityView details →

Gross Margin

54.46%

Net Margin

3.78%

EBITDA Margin

9.09%

ROE (TTM)

1.51%

ROA (TTM)

1.04%

Asset Turnover

0.28x

GrowthView details →

Revenue YoY

−5.14%

EPS YoY

−70.29%

FCF YoY

—

Revenue CAGR 3Y

−4.85%

EPS CAGR 3Y

−45.81%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.19x

Current Ratio

2.21x

Quick Ratio

2.01x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

679.75M

Net Income (TTM)

25.67M

Op. CF (TTM)

−15.50M

Latest newsMore news →

Taienkang's wholly-owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for cisplatin polymer micelles for injection.15d ago

Similar companies

步步高002251.SZ 重药控股000950.SZ 赛维时代301381.SZ 雅创电子301099.SZ 建发致新301584.SZ 友阿股份002277.SZ

Latest newsMore news →

Taienkang's wholly-owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for cisplatin polymer micelles for injection.15d ago